China Biologic Products
In 2010, Warburg Pincus invested in China Biologic Products (CBPO), one of the largest privately operated, integrated plasma-based pharmaceutical companies in China, with a strong product portfolio of different dosage forms of plasma products in three major classes: human albumin, immunoglobin, and coagulation factor products. During Warburg Pincus’ investment tenure, the firm helped CBPO improve corporate governance and management by introducing an experienced CEO and CFO and assisted the company in its opening of new plasma stations. Warburg Pincus also led CBPO’s capital market promotion to increase investor awareness and market liquidity. Warburg Pincus exited CBPO in 2016.
Website Case Studies Disclaimer
The investments described in the case studies are provided for illustrative purposes only and are not, and do not purport to be, representative of all investments, or all types of investments, previously made by Warburg Pincus, or indicative of the performance of all prior Warburg Pincus investments. The case studies have been selected on the basis of objective criteria that Warburg Pincus believes are representative of the firm’s experience partnering with portfolio company management teams, and of the sectors, stages, strategies and/or geographies in which the firm invests. The information provided in the case studies are not necessarily an indication of future results, and may not be relied up for any purpose. Warburg Pincus’ current or future portfolio companies may differ materially in size, type, performance and other characteristics from the investments presented in the case studies. Further, references in this case study should not be construed as a recommendation or offer to buy or sell any particular security or to make any particular investment.